Book contents
- Frontmatter
- Contents
- Contributors
- Overview: Biology Is the Foundation of Therapy
- PART I BASIC RESEARCH
- PART II CLINICAL RESEARCH
- 23 Introduction to Clinical Research
- 24 Sarcoma
- 25 Neuroblastoma
- 26 Retinoblastoma
- 27 Primary Brain Tumors and Cerebral Metastases
- 28 Head and Neck Cancer Metastasis
- 29 Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease
- 30 Gastric Cancer Metastasis
- 31 Metastatic Pancreatic Cancer
- 32 Metastasis of Primary Liver Cancer
- 33 Advances in Management of Metastatic Colorectal Cancer
- 34 Lung Cancer Metastasis
- 35 Metastatic Thyroid Cancer: Evaluation and Treatment
- 36 Metastatic Renal Cell Carcinoma
- 37 Bladder Cancer
- 38 Bone Complications of Myeloma and Lymphoma
- 39 Breast Metastasis
- 40 Gynecologic Malignancies
- 41 Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics
- 42 The Biology and Treatment of Metastatic Testicular Cancer
- 43 Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy
- 44 Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients
- 45 Lymphatic Mapping and Sentinel Lymph Node Biopsy
- 46 Molecular Imaging and Metastasis
- 47 Preserving Bone Health in Malignancy and Complications of Bone Metastases
- 48 Role of Platelets and Thrombin in Metastasis
- THERAPIES
- Index
- References
34 - Lung Cancer Metastasis
from PART II - CLINICAL RESEARCH
Published online by Cambridge University Press: 05 June 2012
- Frontmatter
- Contents
- Contributors
- Overview: Biology Is the Foundation of Therapy
- PART I BASIC RESEARCH
- PART II CLINICAL RESEARCH
- 23 Introduction to Clinical Research
- 24 Sarcoma
- 25 Neuroblastoma
- 26 Retinoblastoma
- 27 Primary Brain Tumors and Cerebral Metastases
- 28 Head and Neck Cancer Metastasis
- 29 Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease
- 30 Gastric Cancer Metastasis
- 31 Metastatic Pancreatic Cancer
- 32 Metastasis of Primary Liver Cancer
- 33 Advances in Management of Metastatic Colorectal Cancer
- 34 Lung Cancer Metastasis
- 35 Metastatic Thyroid Cancer: Evaluation and Treatment
- 36 Metastatic Renal Cell Carcinoma
- 37 Bladder Cancer
- 38 Bone Complications of Myeloma and Lymphoma
- 39 Breast Metastasis
- 40 Gynecologic Malignancies
- 41 Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics
- 42 The Biology and Treatment of Metastatic Testicular Cancer
- 43 Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy
- 44 Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients
- 45 Lymphatic Mapping and Sentinel Lymph Node Biopsy
- 46 Molecular Imaging and Metastasis
- 47 Preserving Bone Health in Malignancy and Complications of Bone Metastases
- 48 Role of Platelets and Thrombin in Metastasis
- THERAPIES
- Index
- References
Summary
Lung cancer ranks among the most common and most lethal malignancies worldwide. In 2006, approximately 174,470 of an estimated 1,399,790 (12%) new cancer cases, and 162,460 of an estimated 564,830 (28%) total cancer deaths, in the United States were attributable to lung cancer. Similarly, in the 38 countries in Europe, lung cancer accounted for 12 percent of approximately 3.2 million new cancer cases and 19.7 percent of cancer-related deaths. Lung cancer is classified into two major groups: non–small-cell lung cancer (NSCLC), which accounts for 75 percent of all cases, and small-cell lung cancer (SCLC), which accounts for approximately 25 percent. NSCLC is further divided into three histologic subtypes: adenocarcinoma (30%–40%), squamous cell carcinoma (SCC; 20%–25%), and large cell carcinoma (15%–20%). Approximately half of patients with NSCLC already have metastatic (stage IV) disease at the time of diagnosis, and survival times are short regardless of the type of chemotherapy administered.
Several platinum-based chemotherapy regimens are available; they generally yield similar outcomes, with median time to progression of four months and median survival of eight months. Compared with other common primary tumors, such as colorectal and breast cancer, where the median survival is more than twenty months, the prognosis of metastatic NSCLC remains extremely poor. Similar to breast cancer, bone and lung metastases are particularly frequent in NSCLC. However, the different distribution patterns of metastases in lung carcinoma are poorly understood, probably because studies are difficult, given the extremely short survival times and high proportion of patients who have widespread metastases at the time of diagnosis.
- Type
- Chapter
- Information
- Cancer MetastasisBiologic Basis and Therapeutics, pp. 369 - 381Publisher: Cambridge University PressPrint publication year: 2011
References
- 2
- Cited by